HOME >> BIOLOGY >> NEWS
Pall tells FDA panel about blood filtering technology

East Hills, NY (Oct. 31, 2005) - - At the request of the Food and Drug Administration (FDA) Transmissible Spongiform Encephalopathies (TSEs) Advisory Committee, Pall Corporation (NYSE: PLL) today presented the latest research results on its prion technology to remove TSE infectivity from blood. The Pall LeukotrapR Affinity Prion Reduction Filter system is the only Council of Europe (CE) marked technology shown to remove prions from red blood cells, the most commonly transfused blood component. Samuel Coker. PhD, Principal Scientist and Technical Director of Pall Medical, who has been spearheading the research effort, gave the Committee a first-hand look at the validation studies on the performance characteristics of the prion reduction technology filter that were used to earn its CE mark in Europe. He also presented new results on quality control measures for blood banks to use upon implementation of prion reduction as a means to prevent transfusion-transmitted variant Creutzfeldt-Jakob Disease (vCJD).

TSEs, also called prion diseases, are fatal neurodegenerative diseases that include vCJD, the human form of bovine spongiform encephalopathy (BSE), or "mad cow disease." The presentation, part of the Advisory Committee's discussion on labeling claims for TSE clearance studies for blood component filters, is a continuation of Pall Corporation's dialogue with U.S. regulatory and health authorities on protecting the blood supply from prions that can cause vCJD.

Studies Validating Filter Performance

Dr. Coker presented research results on the ability of the filter to remove all types of prions from red cells including scrapie (a TSE affecting sheep); mouse infected with human variant CJD (mvCJD) and human sporadic CJD (sCJD). Sporadic CJD is the most common form of CJD affecting people.

He provided results of bioassays to provide a quantitative method to determine log removal of infectious prion in hamsters. (Hamsters are rec
'"/>

Contact: Marcia Katz
marcia_katz@pall.com
516-801-9128
Pall Corporation
31-Oct-2005


Page: 1 2 3

Related biology news :

1. Exercise pill switches on gene that tells cells to burn fat
2. Ancient coral reef tells the history of Kenyas soil erosion
3. Mapping system tells skin cells whether to become scalp, palm tissues, Stanford study finds
4. Scent of a woman tells male redback spiders to find a mate
5. Microbiology text tells stories, offers online resources
6. Researchers find gland that tells fruit flies when to stop growing
7. Its a bugs life: MIT team tells moving tale
8. Immune systems distress signal tells bacteria when to strike back
9. DNA from feathers tells tale of eagle fidelity
10. As the protein folds: The tail of the gene tells the tale of Machado-Joseph disease
11. X-chromosome tells the tale

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pall tells FDA panel about blood filtering technology

(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
(Date:4/30/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has commenced an underwritten public offering of its ... underwriters a 30-day option to purchase up to an ... offered in the public offering. The offering is subject ... as to whether or when the offering may be ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Biodata, ... notebook with integrated protocols and specimen management systems, ... solutions and consulting services for life science research, ... of Labguru’s newest feature: chemical structure and reaction ... features for biologists, bio-chemists, and more, the integration ...
(Date:4/30/2015)... , April 30, 2015 ... Leading Global Biotechnology Company   Shire ... for the three months to March 31, 2015. ... sales $1,423 million +9% +13% Total revenues $1,488 million ... +19% US GAAP operating income from continuing operations $475 ...
(Date:4/30/2015)... CA (PRWEB) April 30, 2015 SureClinical, ... that Julie I. Morris has joined SureClinical’s executive team ... an experienced biotech and technology executive with over 25 ... Fortune 500 companies. , Ms. Morris joins SureClinical ... biotech company. She was CFO of MBI from its ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Julie I. Morris Joins SureClinical as Chief Financial Officer 2
Cached News: